Morphotek, Inc. has entered into a Research, Evaluation and Collaboration Agreement with GlaxoSmithKline to apply Morphotek's proprietary Morphodoma technology to GSK's antibody producer lines to generate cell lines that exhibit new or improved biological characteristics. GSK is the eighth sublicensee of Morphotek's cell line optimization technology platform.

Under the terms of the non-exclusive agreement, Morphotek will receive funding to support research and development efforts for an initial project to be performed for GSK, with the option for GSK to retain Morphotek for two additional projects. Morphotek may also receive annual licensing fees and milestone payments upon the successful achievement of project goals and the advancement of the resultant products through clinical development. GSK will conduct the preclinical and clinical development and subsequent commercialization of all products, release from Morphotek said.

Nicholas C. Nicolaides, president and CEO of Morphotek states, "This exciting collaboration is yet another validation of our technology. We are looking forward to working with the team at GSK and enhancing the quality and value of their proprietary products."

Morphotek, Inc. is a biotechnology company focused on the development of optimized therapeutic antibodies for the treatment of cancer, inflammatory and infectious diseases.